Pharmacological intervention upon the RAS axis is advisable since both spironolactone and Angiotensin-converting enzyme inhibitors proved consistent reduction in PTH and calcium levels, thereby diminishing the toxic potential of elevated PTH and delaying surgical treatment of valvular calcification. Here, PTH is linked to calcification.